Diabetes Drug Makes NASH Vanish in Some Patients (CME/CE)
(MedPage Today) -- Injected liraglutide appears more effective than placebo in liver disease (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 24, 2015 Category: Cardiology Source Type: news
Alzheimer's 'breakthrough': Addenbrooke's Hospital recruits first humans for testing diabetes drug
Patients over 50 with early Alzheimer's recruited for research in Cambridge after study finds drug Liraglutide might reverse some damage caused in later stages of disease (Source: Telegraph Health)
Source: Telegraph Health - April 21, 2015 Category: Consumer Health News Tags: Liraglutide Alzheimer's breakthrough disease Addenbrooke's Hospital Cambridge Source Type: news
Byetta, Victoza, Bydureon: Diabetes drugs and weight loss
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - April 11, 2015 Category: Consumer Health News Source Type: news
Liraglutide and Sitagliptin in Type 2 DiabetesLiraglutide and Sitagliptin in Type 2 Diabetes
Does liraglutide offer greater glycemic contol and weight reduction than sitagliptin in clinical practice? International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Naltrexone/Bupropion Approved as Mysimba for Obesity in EU Naltrexone/Bupropion Approved as Mysimba for Obesity in EU
Naltrexone HCl/bupropion HCl prolonged release joins liraglutide as the second drug to be approved for obesity this week in the European Union. International Approvals (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 27, 2015 Category: Primary Care Tags: Diabetes & Endocrinology News Alert Source Type: news
European Commission Approves Novo Nordisk's Injectable Drug for ObesityEuropean Commission Approves Novo Nordisk's Injectable Drug for Obesity
The European Commission has approved a formulation of Novo Nordisk's diabetes drug, liraglutide, for treating patients of obesity, a disease that affects approximately 10 to 30 percent of adults in the European Union. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 24, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Liraglutide may help overweight and obese adults lose weight safely and effectively
Obesity guidelines recommend an initial weight loss goal of 5 to 10 percent of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 8, 2015 Category: Science Source Type: news
Liraglutide may help overweight and obese adults lose weight safely and effectively
(The Endocrine Society) Obesity guidelines recommend an initial weight loss goal of 5 to 10 percent of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 7, 2015 Category: Global & Universal Source Type: news
liraglutide injection (Saxenda)
Title: liraglutide injection (Saxenda)Category: MedicationsCreated: 2/19/2015 12:00:00 AMLast Editorial Review: 2/19/2015 12:00:00 AM (Source: MedicineNet Weight Management General)
Source: MedicineNet Weight Management General - February 19, 2015 Category: Eating Disorders and Weight Management Source Type: news
liraglutide injection (Saxenda)
Title: liraglutide injection (Saxenda)Category: MedicationsCreated: 2/19/2015 12:00:00 AMLast Editorial Review: 2/19/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - February 19, 2015 Category: Drugs & Pharmacology Source Type: news
Saxenda (liraglutide) for the Treatment of Obesity
Saxenda (liraglutide (rDNA origin)) is a newly approved injection for the treatment of obesity and chronic weight management. (Source: Drug Development Technology)
Source: Drug Development Technology - February 10, 2015 Category: Pharmaceuticals Source Type: news
Real-world usage and cost of exenatide and liraglutide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news
Miracle of daily diet jab
Packing almost twice the power of rival drugs, liraglutide, made by Novo Nordisk of Denmark, also lowers blood pressure, raises good cholesterol and prevents diabetes. (Source: the Mail online | Health)
Source: the Mail online | Health - January 24, 2015 Category: Consumer Health News Source Type: news
Liraglutide (Saxenda) Gets Okay From EU for Obesity Liraglutide (Saxenda) Gets Okay From EU for Obesity
The injectable GLP-1 agonist liraglutide, long available for the treatment of type 2 diabetes, nears the market in Europe for weight loss, hard on the heels of its US approval for the same indication. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 23, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Insulin Degludec/Liraglutide Combo Available in Switzerland Insulin Degludec/Liraglutide Combo Available in Switzerland
A new product combining a GLP-1 agonist with insulin degludec, which has been hailed the "most powerful combo" to date for type 2 diabetes, has been launched in its first market, Switzerland. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 21, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
